Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Investor Presentation (May 2022)
19 slides from Alaunos Therapeutics's investor presentation, May 2022
Slide 1: Attacking Solid Tumors with Novel TCR-T Cell Therapies
Attacking Solid Tumors with Novel TCR-T Cell Therapies May 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will
Slide 3: Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors
Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors Vision 2022 – Execution Mindset, Delivering Results Phase 1/2 TCR-T Library Trial Enrolling; FPI anticipated 1H22, interim data expected Weaponizing the 1 2H22 immune system with powerful TCRs to treat 2 Clinical Libra
Slide 4: TCR-T Platform with Multiple Solid Tumor Programs in Pipeline
TCR-T Platform with Multiple Solid Tumor Programs in Pipeline PROGRAM TARGETS INDICATION DISCOVERY PRECLINICAL IND-ENABLING PHASE 1 Lung Colon/rectum Library TCR-T cell Therapy KRAS, TP53 & EGFR Endometrium Hotspot Mutations Pancreas (Company Sponsored at MDACC) Ovary Bile Duct mbIL-15 KRAS & TP53 S
Slide 5: TCR-T is Superior to Other Cell Therapy Approaches for Solid Tumors
TCR-T is Superior to Other Cell Therapy Approaches for Solid Tumors TCR-T CAR-T TIL Target Intracellular & Extracellular Antigens Proven Efficacy in Solid Tumors Defined Target Specificity Targets Somatic Neoantigens Established Transposon-based Gene Transfer 5 Table above not based on head-to-head
Slide 6: A Differentiated TCR-T Program Targeting Solid Tumors
A Differentiated TCR-T Program Targeting Solid Tumors Targeting Hotspot Sleeping Beauty hunTRTM Platform Mutations Technology (human neoantigen T cell Receptor) Hotspot mutations are Non-viral transposition ideal targets for technology has favorable Robust discovery engine defeating cancer safety pr
Slide 7: Our TCR-T Cell Platform Targets Solid Tumors in Large Patient Populations
Our TCR-T Cell Platform Targets Solid Tumors in Large Patient Populations with Unmet Clinical Need Cancer Type 2022 Incidence - USA • In the US, 92% of new cancer cases Lung 236,740 are solid tumors Colon and Rectum 151,030 • 4,804 patients are diagnosed every day with cancerous solid tumor Endometr
Slide 8: KRAS, TP53, EGFR Mutations are Commonly Expressed in Targeted Indications
KRAS, TP53, EGFR Mutations are Commonly Expressed in Targeted Indications High frequency tumor targets, not expressed in normal tissues Killer TCR-T cells specific for the mutation without off-tumor toxicity Unmet clinical need for patients with solid tumors 8 Source: Catalogue of Somatic Mutations
Slide 9: TCRs Can Give Patients' T Cells a New Ability to Recognize and Kill Tumor Cells
TCRs Can Give Patients' T Cells a New Ability to Recognize and Kill Tumor Cells with Common Mutations 9
Slide 10: TCR Library Captures High Frequency Mutations and HLA Types
TCR Library Captures High Frequency Mutations and HLA Types • Common HLAs are represented in our TCR library • Certain mutations have more than one HLA restriction • As more TCRs are added to our library, the addressable patient market size will further increase 10
Slide 11: Non-viral Sleeping Beauty Platform for Manufacturing TCR-T Cells
Non-viral Sleeping Beauty Platform for Manufacturing TCR- T Cells • Efficient integration without the complexity of gene editing or viral approaches • Rapid, cost-effective manufacturing • Flexible approach to add TCRs; attractive choice for library • Platform can accommodate large transgene size •
Slide 12: TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells
TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells Powerful TCRs: Naturally-occurring, high avidity TCRs recognize low levels of neoantigens No off-target toxicity observed: Specificity for the mutation with negligible recognition of the wild type sequences Tumor killing: Re
Slide 13: Actively Enrolling First-in-Human TCR-T Clinical Trial with Innovative Library Approach
Actively Enrolling First-in-Human TCR-T Clinical Trial with Innovative Library Approach Trial enrolling patients where a TCR matching a neoantigen / HLA pairing is available in our TCR-T library. Phase I Objectives: Phase I is a prospective, open-label, dose-escalation study of TCR-T cells in patien
Slide 14: Each Autologous TCR-T Cell Product is Manufactured with a Matched TCR
Each Autologous TCR-T Cell Product is Manufactured with a TCR Matched for the Patient’s Mutation and HLA Type Screening 1 Infusion 6 2 Selection of TCR from Library for Manufacturing 5 3 TCR Expression & Peripheral Blood Expansion Leukapheresis 4 Sleeping Beauty Transposition of TCR 14
Slide 15: State of the Art, In-House cGMP Manufacturing Facility Operational
State of the Art, In-House cGMP Manufacturing Facility Operational Provides control Located in over clinical Houston near Texas TCR-transposed T cells targeting manufacturing, including Medical Center neoantigens have been grown: expertise and scheduling with high TCR expression to clinical dose lev
Slide 16: hunTR Program Rapidly Expands TCR Library Targeting Hotspot Mutations
hunTRTM Program Rapidly Expands TCR Library Targeting Hotspot Mutations Focus on neoantigens, particularly those arising from hotspot mutations Empirical screening of TCRs from CD4+ and CD8+ T cells directly from tumor High-throughput TCR screening 16
Slide 17: mbIL-15 Improves the Persistence and Anti-tumor Activity of TCR-T cells
mbIL-15 Improves the Persistence and Anti-tumor Activity of TCR-T cells in the Tumor Microenvironment (TME) Pro-survival signaling limits negative signals from the TME Stem-cell memory mbIL-15 TCR-T cells regenerate TCR-T cells Limit effects of HLA loss by supporting TILs and NK cells Potential for
Slide 18: Experienced Management Team
Experienced Management Team Kevin S. Boyle, Sr. Melinda Lackey Chief Executive Officer SVP Legal Drew Deniger, PhD Mike Wong VP Research & Development VP Finance Melinda Lackey 18
Slide 19: Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors
Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors Vision 2022 – Execution Mindset, Delivering Results Phase 1/2 TCR-T Library Trial Enrolling; FPI anticipated 1H22, interim data expected Weaponizing the 1 2H22 immune system with powerful TCRs to treat 2 Clinical Libra
Alaunos Therapeutics — Investor Presentation (May 2022) on 6ix